Chemical Compound Review:
Augmentin (2R,5R,6S)-6-[[(2R)-2-amino- 2-(4...
Synonyms:
Amoxyclav, Curam, SureCN591660, CHEMBL2097107, AC1O5KQV, ...
Brook,
Shah,
Destache,
Dewan,
O'Donohue,
Campbell,
Angelillo,
Hakanen,
Lehtopolku,
Siitonen,
Huovinen,
Kotilainen,
Garau,
Twynholm,
Garcia-Mendez,
Siquier,
Rivero,
Palmer,
Higgins,
Herring,
Kingston,
Cazzola,
Salvatori,
Dionisio,
Allegra,
Breuil,
Brisabois,
Casin,
Armand-Lefèvre,
Frémy,
Collatz,
Vree,
Dammers,
Exler,
Mimoz,
Schaeffer,
Incagnoli,
Louchahi,
Edouard,
Petitjean,
Tod,
- Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. van Balen, F.A., de Melker, R.A., Touw-Otten, F.W. Lancet (1996)
- Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. Kenyon, S.L., Taylor, D.J., Tarnow-Mordi, W. Lancet (2001)
- Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Kaiser, L., Lew, D., Hirschel, B., Auckenthaler, R., Morabia, A., Heald, A., Benedict, P., Terrier, F., Wunderli, W., Matter, L., Germann, D., Voegeli, J., Stalder, H. Lancet (1996)
- Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis. Turner, P., Edwards, R., Weston, V., Gazis, A., Ispahani, P., Greenwood, D. Lancet (1995)
- In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin. Prieto, J., Aguilar, L., Giménez, M.J., Toro, D., Gómez-Lus, M.L., Dal-Ré, R., Balcabao, I.P. Antimicrob. Agents Chemother. (1998)
- Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. Cazzola, M., Salvatori, E., Dionisio, P., Allegra, L. Pulmonary pharmacology & therapeutics. (2006)
- Improved phagocyte response by co-amoxiclav in renal transplant recipients. Cuffini, A.M., Tullio, V., Giacchino, F., Bonino, A., Mandras, N., Bianchi, N., Roana, J., Scalas, D., Bonello, F., Carlone, N.A. Transplantation (2001)
- Co-amoxiclav levels in bronchial mucosa. Honeybourne, D., Andrews, J.M., Wise, R. Thorax (1995)
- Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis. Chierakul, W., Wangboonskul, J., Singtoroj, T., Pongtavornpinyo, W., Short, J.M., Maharjan, B., Wuthiekanun, V., Dance, D.A., Teparrukkul, P., Lindegardh, N., Peacock, S.J., Day, N.P., Chaowagul, W., White, N.J. J. Antimicrob. Chemother. (2006)
- Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. Ferwerda, A., Moll, H.A., Hop, W.C., Kouwenberg, J.M., Tjon Pian Gi, C.V., Robben, S.G., de Groot, R. J. Antimicrob. Chemother. (2001)
- Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. Hoogkamp-Korstanje, J.A., Dirks-Go, S.I., Kabel, P., Manson, W.L., Stobberingh, E.E., Vreede, R.W., Davies, B.I. J. Antimicrob. Chemother. (1997)
- Antibiotic resistance in salmonellae isolated from humans and animals in France: comparative data from 1994 and 1997. Breuil, J., Brisabois, A., Casin, I., Armand-Lefèvre, L., Frémy, S., Collatz, E. J. Antimicrob. Chemother. (2000)
- Effect of amoxicillin and co-amoxiclav on the aerobic and anaerobic nasopharyngeal flora. Brook, I., Gober, A.E. J. Antimicrob. Chemother. (2002)
- Co-amoxiclav pharmacokinetics during posttraumatic hemorrhagic shock. Mimoz, O., Schaeffer, V., Incagnoli, P., Louchahi, K., Edouard, A., Petitjean, O., Tod, M. Crit. Care Med. (2001)
- Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. Vree, T.B., Dammers, E., Exler, P.S. J. Antimicrob. Chemother. (2003)
- Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. Garau, J., Twynholm, M., Garcia-Mendez, E., Siquier, B., Rivero, A. J. Antimicrob. Chemother. (2003)
- Pyelonephritis caused by multiple clones of Escherichia coli, susceptible and resistant to co-amoxiclav, after a 45 day course of co-amoxiclav. Leflon-Guibout, V., Bonacorsi, S., Clermont, O., Ternat, G., Heym, B., Nicolas-Chanoine, M.H. J. Antimicrob. Chemother. (2002)
- Use of PCR in the diagnosis of early syphilis in the United Kingdom. Palmer, H.M., Higgins, S.P., Herring, A.J., Kingston, M.A. Sexually transmitted infections. (2003)
- High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. Masterton, R.G., Bochsler, J.A. J. Antimicrob. Chemother. (1995)
- Antimicrobial treatment of an experimental otitis media caused by a beta-lactamase positive isolate of Haemophilus influenzae. Ponte, C., Cenjor, C., Parra, A., Nieto, E., García-Calvo, G., Giménez, M.J., Aguilar, L., Soriano, F. J. Antimicrob. Chemother. (1999)
- Amoxycillin/clavulanic acid combinations increase transmigration of leucocytes through endothelial cell monolayers: endothelial cells play a key role. Hofbauer, R., Moser, D., Gmeiner, B., Kaye, A.D., Kapiotis, S., Wagner, O., Frass, M. J. Antimicrob. Chemother. (1999)
- Effect of amoxycillin with or without clavulanate on adenoid bacterial flora. Brook, I., Shah, K. J. Antimicrob. Chemother. (2001)
- Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. Leflon-Guibout, V., Ternat, G., Heym, B., Nicolas-Chanoine, M.H. J. Antimicrob. Chemother. (2002)
- Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. Destache, C.J., Dewan, N., O'Donohue, W.J., Campbell, J.C., Angelillo, V.A. J. Antimicrob. Chemother. (1999)
- The in-vitro susceptibilities of vaginal lactobacilli to four broad-spectrum antibiotics, as determined by the agar dilution and E test methods. Herra, C.M., Cafferkey, M.T., Keane, C.T. J. Antimicrob. Chemother. (1995)
- Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. Milazzo, I., Blandino, G., Caccamo, F., Musumeci, R., Nicoletti, G., Speciale, A. J. Antimicrob. Chemother. (2003)
- Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. Soriano, F., Ponte, C., Nieto, E., Parra, A. J. Antimicrob. Chemother. (1996)
- Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non-malignant conditions: a double-blind prospective randomized controlled trial. Saadeddin, A., Freshwater, D.A., Fisher, N.C., Jones, B.J. Aliment. Pharmacol. Ther. (2005)
- Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. Bonfiglio, G., Livermore, D.M. J. Antimicrob. Chemother. (1993)
- Gentamicin- and methicillin-resistant Staphylococcus aureus: phenotypic and genotypic characterization of three putative nosocomial outbreak strains. Traub, W.H., Leonhard, B., Bauer, D. Chemotherapy. (1996)
- Reduced susceptibility to co-amoxiclav in Escherichia coli, Salmonella typhimurium and Klebsiella pneumoniae isolated in Romania between 1985 and 1993. Espinasse, F., Gheorghiu, R., Poiata, A., Labia, R., Nicolas-Chanoine, M.H. J. Antimicrob. Chemother. (1997)
- Antimicrobial resistance in Haemophilus influenzae from England and Scotland in 1991. Powell, M., Yeo, S.F., Seymour, A., Yuan, M., Williams, J.D., Fah, Y.S. J. Antimicrob. Chemother. (1992)
- Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-2000. Hakanen, A.J., Lehtopolku, M., Siitonen, A., Huovinen, P., Kotilainen, P. J. Antimicrob. Chemother. (2003)
- A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. Hoepelman, A.I., Sips, A.P., van Helmond, J.L., van Barneveld, P.W., Neve, A.J., Zwinkels, M., Rozenberg-Arska, M., Verhoef, J. J. Antimicrob. Chemother. (1993)
- Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers. Alou, L., Aguilar, L., Sevillano, D., Giménez, M.J., Laguna, B., Echeverría, O., Carcas, A., Lubomirov, R., Casal, J., Prieto, J. J. Antimicrob. Chemother. (2005)
- Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. Van Kerkhoven, D., Peetermans, W.E., Verbist, L., Verhaegen, J. J. Antimicrob. Chemother. (2003)